LU 58463

Drug Profile

LU 58463

Latest Information Update: 24 Jan 2013

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Abbott GmbH & Co. KG
  • Class Antithrombotics; Peptides
  • Mechanism of Action Thrombin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Thromboembolism; Venous thrombosis

Most Recent Events

  • 01 Aug 1997 Investigation in Thromboembolism (Unknown route)
  • 01 Aug 1997 Investigation in Venous thrombosis (Unknown route)
  • 03 Jun 1997 No-Development-Reported for Thromboembolism (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top